GIST Support Wiki

 
TRIAL: A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib

A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST)

For more information see web site: http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12614000950662


Main Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.

Register: ANZCTR Last refreshed on: 13 October 2014 Main ID: ACTRN12614000950662 Date of registration: 04/09/2014

Primary sponsor: Other Collaborative groups Australasian Gastro-Intestinal Trials Group (AGITG)

Public title: A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST)

Scientific title: A phase II trial to determine if an alternating regimen of imatinib and regorafenib has sufficient activity and safety to warrant further evaluation as a first line treatment for metastatic GIST.

Date of first enrolment: 1/10/2014

Target sample size: 240

Recruitment status: Not yet recruiting

URL: http://www.anzctr.org.au/ACTRN12614000950662.aspx

Study type: Interventional

Study design: Randomised controlled trial Parallel

Phase: Phase 2 Countries of recruitment: Australia,Outside Belgium Finland France Norway Sweden

Contacts Name: Ms ALTGIST Trial Coordinator Address: NHMCR CTC Locked Bag 77 Camperdown, NSW, 1450, Australia Telephone: +61 2 9562 5000 Email: altgist@ctc.usyd.edu.au Affiliation:

Name: Ms ALTGIST Trial Coordinator Address: NHMCR CTC Locked Bag 77 Camperdown, NSW, 1450, Australia Telephone: +61 2 9562 5000 Email: altgist@ctc.usyd.edu.au